Orchestra BioMed (OBIO) Competitors

Butterfly Network (NYSE:BFLY) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Is BFLY or OBIO more profitable?

Butterfly Network has a net margin of -71.79% compared to Orchestra BioMed's net margin of -2,367.49%. Butterfly Network's return on equity of -30.53% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-71.79%	-30.53%	-21.80%
Orchestra BioMed	-2,367.49%	-289.42%	-110.04%

Which has better valuation and earnings, BFLY or OBIO?

Orchestra BioMed has lower revenue, but higher earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$82.06M	4.68	-$72.49M	-$0.28	-5.45
Orchestra BioMed	$2.64M	37.32	-$61.02M	-$1.83	-1.39

Which has more risk & volatility, BFLY or OBIO?

Butterfly Network has a beta of 2.45, meaning that its stock price is 145% more volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.

Do analysts rate BFLY or OBIO?

Butterfly Network presently has a consensus price target of $3.00, indicating a potential upside of 96.72%. Orchestra BioMed has a consensus price target of $14.00, indicating a potential upside of 449.02%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Orchestra BioMed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Do institutionals and insiders believe in BFLY or OBIO?

37.9% of Butterfly Network shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 25.2% of Butterfly Network shares are held by insiders. Comparatively, 8.1% of Orchestra BioMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media prefer BFLY or OBIO?

In the previous week, Orchestra BioMed had 7 more articles in the media than Butterfly Network. MarketBeat recorded 12 mentions for Orchestra BioMed and 5 mentions for Butterfly Network. Butterfly Network's average media sentiment score of 0.71 beat Orchestra BioMed's score of -0.01 indicating that Butterfly Network is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Orchestra BioMed	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Butterfly Network beats Orchestra BioMed on 8 of the 15 factors compared between the two stocks.